Inhaled nitric oxide calculation in preterm
Reading File
Finding Sources
Finding Sources
Searching PubMed
"inhaled nitric oxide" AND "preterm infants"
Finding Sources
Finding Sources
Searching the Web
inhaled nitric oxide dosing calculation preterm neonate ppm formula methemoglobin
Reading File
Finding Sources
Finding Sources
Reading Web Page
https://cps.ca/en/documents/position/inhaled-nitric-oxide
Inhaled Nitric Oxide (iNO) in Preterm Infants — Dosing/Calculation
1. Important caveat first
Unlike term/late-preterm infants with PPHN, routine use of iNO in preterm infants (<34-35 weeks GA) is not evidence-supported and is generally reserved for specific rescue scenarios (severe hypoxic respiratory failure with echocardiographic pulmonary hypertension, preterm prelabor rupture of membranes with pulmonary hypoplasia). Meta-analyses show no consistent reduction in death/BPD and a signal of possible increased severe IVH (grade 3-4) with iNO in preterm infants (RR 1.20, 95% CI 0.98-1.47) - Canadian Paediatric Society position statement. So "calculating" a dose only applies once a clinician has decided iNO is indicated for an individual preterm infant.
2. Deciding whether to start - Oxygenation Index (OI)
Most protocols use the OI to gauge severity of hypoxic respiratory failure and trigger iNO:
OI = (Mean Airway Pressure × FiO₂ × 100) / PaO₂ (mmHg)
- OI ≥ 15-20, or FiO₂ ≥ 0.6 on invasive ventilation, is generally used to define hypoxic respiratory failure warranting consideration of pulmonary vasodilator therapy - Harriet Lane Handbook, p. 652 (Chapter on Respiratory Distress/PPHN).
- Severe HRF in preterm trials (e.g., Van Meurs et al.) was defined as OI ≥ 10.
3. Starting dose calculation for preterm infants
| Population | Starting dose | Max useful dose |
|---|---|---|
| Term/late preterm | 20 ppm | up to 40 ppm |
| Very/extremely preterm (<32-35 wk) | 5-10 ppm | escalate to 20 ppm if no response; little added benefit beyond 20 ppm, and higher doses may worsen V/Q matching in preterm parenchymal lung disease |
- The Harriet Lane Handbook notes: "Typical starting dose is 20 ppm, though research suggests lower doses in premature neonates (10 ppm) may be sufficient. Unlikely to have additional benefit at >40 ppm."
- Clinical response (improved oxygenation, ↑SpO₂ ≥5%, or ↑PaO₂ ≥20 mmHg) is assessed within 30-60 minutes. If no response after this trial, iNO should be discontinued rather than escalated further.
4. Delivery/gas-blending calculation (practical device math)
iNO is delivered by blending a high-concentration NO source cylinder (typically 800 ppm) into the ventilator inspiratory limb. The flow of source gas needed to achieve the target ppm is:
NO flow (L/min) = [Desired ppm × Total inspired gas flow (L/min)] / (Cylinder concentration in ppm − Desired ppm)
Modern delivery systems (e.g., INOmax DSIR) calculate this automatically from the ventilator's measured inspiratory flow, but the underlying dilution principle is as above. Nitrogen dioxide (a toxic breakdown product) must be kept below 0.5-2 ppm; if it rises, the NO concentration must be reduced.
5. Weaning calculation
- Once a clinical response is established and FiO₂ has weaned to ≤0.6: reduce iNO from 20 ppm down to 5 ppm in decrements of 5 ppm every 2-4 hours (provided OI stays ≤10, pre-ductal SpO₂ does not fall ≥5%, FiO₂ does not rise ≥10%).
- Below 5 ppm, wean by 1 ppm every 30 minutes-2 hours until discontinuation.
- Avoid abrupt cessation - rebound severe hypoxemia and pulmonary hypertension can occur, especially if stopped rapidly from a low dose.
6. Safety monitoring built into the "calculation"
- Methemoglobin: check within a few hours of starting (steady state can take up to 8 hours); many units reduce/wean iNO if MetHb >2-4%, definite toxicity concern >2.5-4%.
- NO₂: keep <0.5-2 ppm; reduce NO dose if it rises above threshold.
- Monitor platelet function/bleeding risk (iNO decreases platelet aggregation) - particularly relevant given the IVH signal in preterm infants.
Recent evidence check (PubMed, last 2-3 years, systematic reviews/meta-analyses)
- Zhou et al. 2025, systematic review/meta-analysis on iNO in preterm respiratory disease (PMID: 40877918)
- Baczynski et al. 2023, meta-analysis on oxygenation response and survival with rescue iNO in preterm hypoxemia (PMID: 37542786)
- Zheng et al. 2023, meta-analysis on iNO for BPD prevention in premature infants (PMID: 36991371)
These generally reinforce the textbook position: no clear mortality/BPD benefit from routine preterm use, reserved for rescue in refractory hypoxic respiratory failure with confirmed pulmonary hypertension, using lower starting doses (5-10 ppm) than term infants.
If you're working through a specific clinical scenario (particular gestational age, OI, ventilator flow settings), give me those numbers and I can walk through the exact dose/flow calculation for that case.
This is a shared conversation. Sign in to Orris to start your own chat.